➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
Medtronic
McKinsey
Mallinckrodt

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Degarelix acetate - Generic Drug Details

» See Plans and Pricing

« Back to Dashboard

What are the generic sources for degarelix acetate and what is the scope of patent protection?

Degarelix acetate is the generic ingredient in one branded drug marketed by Ferring and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Degarelix acetate has one hundred and thirty-six patent family members in thirty-six countries.

One supplier is listed for this compound.

Summary for degarelix acetate
International Patents:136
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 33
Clinical Trials: 27
Patent Applications: 12
Formulation / Manufacturing:see details
DailyMed Link:degarelix acetate at DailyMed
Recent Clinical Trials for degarelix acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Charles G. DrakeEarly Phase 1
Bristol-Myers SquibbEarly Phase 1
Ferring PharmaceuticalsEarly Phase 1

See all degarelix acetate clinical trials

Paragraph IV (Patent) Challenges for DEGARELIX ACETATE
Tradename Dosage Ingredient NDA Submissiondate
FIRMAGON POWDER;SUBCUTANEOUS degarelix acetate 022201 2019-12-20

US Patents and Regulatory Information for degarelix acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-002 Dec 24, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for degarelix acetate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1003774 122009000033 Germany   Start Trial PRODUCT NAME: DEGARELIX, GGF. IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON, WIE DEM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001-002 20090217
1003774 PA2009005 Lithuania   Start Trial PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
1003774 91585 Luxembourg   Start Trial PRODUCT NAME: DEGARELIX, EVENTUELLEMENT UN SEL PHARMACEUTIQUEMENT ACCEPTABE, TEL QUE L'ACETATE (FIRMAGON); REG. DATE: 20090217
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Colorcon
Medtronic
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.